ClinicalTrials.gg
RecruitingNCT06763055INTERACT5Updated Jul 8, 2026

The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

A Phase 3 interventional study of Colchicine 0.5 mg and Deferoxamine Mesylate in Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage and Supratentorial Intracerebral Haemorrhage, sponsored by The George Institute. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by The George Institute · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Cerebral Hemorrhage with a site in Australia — 5 open to participants now, 6 under way, 2 of them phase 3. Cerebral Hemorrhage · Australia.

Planned enrollment
5th of 18
2,000 · median 452
Started
2025
with 1 other
Phase 3
6 of 20
2 open now
Registered
19th of 20
by date
Lead sponsor
9 of 20
The George Institute

Among the 20 studies in Cerebral Hemorrhage with a site in Australia, this one is the 5th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 3, and was the 19th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

5 of the 20 studies in Cerebral Hemorrhage with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Cerebral Hemorrhage with a site in Australia, or all of them as a file.
02

Study summary

This is a domain within the ACT-GLOBAL platform trial to compare the effectiveness of early and appropriate pharmacological interventions in acute intracerebral hemorrhage (ICH) to control secondary brain injury. Up to 2000 patients with presumed spontaneous supratentorial intracerebral hemorrhage (ICH) will be followed for 6 months (or death, if prior to 6 months).

Adaptive interim analyses will be used, with statistical triggers to determine if any of the interventions are superior to control. The end of the trial is defined as the date that all participants have completed their 6-month assessment.

A large amount of preclinical data indicates that the outcome from ICH is linked to the detrimental effects of breakdown substances from brain bleeds. However, there remains a lack of compelling evidence supporting the effectiveness of any pharmacological intervention that can mitigate the secondary cerebral injury. The INTERACT domain aims to assess the effectiveness of intravenous deferoxamine and low-dose oral colchicine, both individually and in combination, to standard of care alone, on improving functional outcome in patients with spontaneous supratentorial ICH.

Those patients who meet eligibility criteria will be randomized to receive one of four interventions:

  1. No deferoxamine mesylate and no colchicine (labeled as control)
  2. Deferoxamine mesylate only: deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days.
  3. Colchicine only: 0.5mg of oral colchicine daily for 30 consecutive days.
  4. Both deferoxamine mesylate and colchicine: deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days.
Read the detailed description

Intracerebral hemorrhage (ICH) is a severe type of stroke, responsible for substantial disability and death worldwide. It accounts for 6.5% to 19.6% of all strokes, with incidence rates increasing, especially in low- and middle-income countries. Survivors often face significant consequences, including functional impairments, recurrent strokes, cognitive decline, and depression.

Despite advancements in acute stroke care, there are few effective treatments specifically targeting the brain damage caused by ICH. Previous research has identified that the formation of perihaematomal oedema (PHE) is a critical factor in poor recovery, making it a key focus for therapeutic development.

INTERACT5 domain will focus on two promising medications. Deferoxamine, an iron-chelating agent, targets oxidative stress caused by iron released from damaged brain tissue. Studies suggest it may reduce brain swelling and secondary injury after ICH. Colchicine, an anti-inflammatory medication, inhibits pathways involved in inflammation, which may help minimize brain damage. INTERACT5 will enroll patients aged 18-80 with acute spontaneous supratentorial ICH, confirmed through imaging, who present to the hospital within 24 hours of symptom onset. Other domain-specific inclusion criteria:

  • Hematoma volume ≥≥10 mL or any volume post-surgery
  • NIHSS score >8
  • GCS ≥8>7

Participants will be randomized to one of four groups: standard care, deferoxamine alone, colchicine alone, or both treatments combined. Deferoxamine will be administered intravenously (32 mg/kg/day within 1 hour and continued for 2 consecutive days), and colchicine will be given orally (0.5 mg daily for 30 days).

The study's primary outcome is the improvements in functional outcomes at 6 months, measured by the modified Rankin Scale (mRS). Secondary outcomes include EQ-5D-5L at 6 months, changes in PHE size, NIHSS scores, length of hospital stay, ambulatory status at discharge and safety indicators such as mortality at 6 months/SAEs to 6 month, kidney and liver function.

Response Adaptive Randomization (RAR) will be used in this domain to allow readjustment of recruitment towards treatment arms with more favorable emerging effects. Randomization will use minimization method to minimize the imbalance between the number of patients in each treatment group over a number of factors including region, location (deep vs cortical)age (>65 vs ≤65 years old), sex (male vs female), time from onset (>6 vs ≤6 hours), haematoma volume (10-29 vs ≥30 mL), receipt of any decompressive surgery (yes vs no), and intraventricular extension of ICH, etc.

03

Conditions studied

  • Intracerebral Hemorrhage
  • Spontaneous Intracerebral Hemorrhage
  • Supratentorial Intracerebral Haemorrhage
  • Acute Intracerebral Haemorrhage
  • Acute Stroke

Keywords

  • Stroke
  • Acute Stroke
  • ICH
  • Intracerebral Hemorrhage
  • Platform Trial
  • Adaptive Platform Trial
  • Supratentorial ICH
  • secondary brain injury
  • deferoxamine mesylate
  • colchicine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Age between 18 and 80 years old
  2. Diagnosis of presumed spontaneous supratentorial intracerebral haemorrhage, confirmed by brain imaging
  3. Presentation to hospital within 24 hours of symptom onset (or last seen well)
  4. Hematoma volume ≥10 mL or any volume post-surgery
  5. NIHSS score >8
  6. GCS ≥8
  7. Provide written by patient (or approved surrogate)

Exclusion Criteria:

  1. Secondary cause of haemorrhage (e.g., structural abnormality such as arteriovenous malformation, cerebral aneurysm, tumour, trauma), or haemorrhagic transformation of acute ischaemic stroke
  2. Isolate intraventricular haemorrhage
  3. Chronic Kidney Disease
  4. Very high likelihood of death within 7 days or poor adherence to study treatment or follow-up
  5. Severe comorbid disease that will interfere with outcome assessments (e.g., cancer, chronic airflow disease, heart failure, significant disability)
  6. Women who are pregnant or lactating

    Exclusion Criteria related to use of deferoxamine:

  7. Previous chelation therapy or known to deferoxamine products;
  8. Severe iron deficiency anaemia ( \<7 g/dL or requiring regular blood transfusions);
  9. Taking iron supplements containing >325 mg of ferrous iron;
  10. Serum creatinine >2 mg/dL;
  11. Patients with known heart failure taking >500 mg of vitamin C

    Exclusion criteria related to the use of colchicine:

  12. Allergic to colchicine
  13. Myelodysplastic hypoplasia, or liver or severe renal failure
  14. Use of medication which may interact with colchicine (e.g., strong CYPsA4 inhibitors such as ketoconazole, strong P-glycoprotein inhibitors such as fluconazole)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
2,000 participants (estimated)

Study arms

  • Placebo comparator
    No deferoxamine mesylate, No colchicine (control)

    The group will not receive deferoxamine mesylate or colchicine

    Other: Control (Standard treatment)

  • Active comparator
    Deferoxamine mesylate only

    The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) of randomization and continued for 2 consecutive days.

    Drug: Deferoxamine Mesylate

  • Active comparator
    Colchicine only

    The intervention group will receive 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.

    Drug: Colchicine 0.5 mg

  • Active comparator
    Both deferoxamine mesylate and colchicine

    The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.

    Drug: Colchicine 0.5 mg · Drug: Deferoxamine Mesylate

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention group will receive 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.

  • DrugDeferoxamineStudies of DeferoxamineDeferoxamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days

    Also known as: Yes DX

  • OtherControl (Standard treatment)

    The group will not receive deferoxamine mesylate or colchicine

06

What researchers measure

Primary outcomes

  1. mRS scores at 6 months analysed with utility-weights

    Modified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favorable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

    Time frame: From enrollment to the 6 month assessment

Secondary outcomes

  1. Excellent functional neurological outcome (mRS 0-1) at 6 months

    Modified Rankin Scale (mRS) with scores of 0 to 1 indicating a favorable outcome without or with symptoms but no disability.

    Time frame: From enrollment to the 6 month assessment

  2. Independent functional neurological outcome (mRS 0-2) at 6 months

    Modified Rankin Scale (mRS) with scores of 2 to 5 indicating increasing levels of disability (and dependency).

    Time frame: From enrollment to the 6 month assessment

  3. Health-related quality of life, as measured by the EQ-5D-5L at month 6

    The EQ-5D-5L is a generic instrument for describing and valuing health. It is based on a descriptive system that defines health in terms of five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has five response categories corresponding to: no problems, slight, moderate, severe and extreme problems. The version of the instrument selected for the trial is interviewer administered either in-person, or by telemedicine or by telephone. The respondents will also rate their overall health on the day of the interview on a 0-100 visual analogue scale (EQ-VAS).

    Time frame: Completed by telephone at the Day 90 assessment (Day 90 outcomes are assessed in a blinded manner)

  4. Ordinal shift in the 7 levels of mRS at 6 months

    Modified Rankin Scale (mRS) in which scores of 0 to 1 indicate a favorable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

    Time frame: Done at the 6-month assessment (assessed in a blinded manner)

  5. Disability (mRS 3-5) at 6 months

    Modified Rankin Scale (mRS) in which scores of 0 to 1 indicate a favorable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

    Time frame: Done at the 6-month assessment (assessed in a blinded manner)

  6. NIHSS score at Day 7 and Day 14 (or discharge if earlier)

    The National Institutes of Health Stroke Scale to measure severity of stroke on scale 0-42.

    Time frame: Assessment performed at Day 7 and Day 14 (or discharge if earlier)

  7. PHE at Day 7 and Day 14 (or discharge if earlier)

    Perihaematomal oedema (PHE) from CT imaging data assessed at Day 7 and Day 14 (or discharge if earlier)

    Time frame: Day 7 and Day 14 (or discharge if earlier)

  8. Total length of initial hospital stay

    Total length of initial hospital stay within 6 months after stroke onset

    Time frame: Within 6 months after stroke onset

  9. Ambulatory status at hospital discharge

    Assessing mobility of the patient at discharge from hospital

    Time frame: At the time when patient is discharged from enrolling hospital, within 6 months after stroke onset

  10. Place of residence at 6 months

    Assessing the patient's residence at the 6 month follow up. (example: home, rehabilitation, long term care, remains hospitalized)

    Time frame: Completed at the 6-month follow-up visit

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Domain information and tabular trial results will be posted on the National Institutes of Health's website www.clinicaltrials.gov within one year of domain completion.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jan 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Jan 8, 2025
StartActual
Feb 27, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06763055
Lead sponsor
The George Institute
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Feb 27, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 8, 2026

Study contacts

Xiaoying Chen, PhD BPharm BMgt
Contact
xchen@georgeinstitute.org.au
4039448107
Craig Anderson, MD
Contact
canderson@georgeinstitute.org.au
4039448107

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Colchicine · Deferoxamine

Start the discussion